Joint Session of the ESR and EORTC

ESR/EORTC - Current status of breast cancer imaging in clinical trials

1

05:00Wolfgang Gerhard Kunz, Munich / DE

2

25:00Daniela Elena Oprea-Lager, Nijmegen / NL

3

25:00Frédéric Lecouvet, Brussels / BE

4

25:00Lioe-Fee De Geus-Oei, Leiden / NL

5 min

Chairperson's introduction

Wolfgang Gerhard Kunz, Munich / Germany

25 min

Oligometastatic breast cancer screening in clinical trials

Daniela Elena Oprea-Lager, Nijmegen / Netherlands

To learn which imaging modalities provide a more accurate diagnosis of oligometastatic disease.
To become familiar with the current guidelines.
To understand the use of modern imaging modalities in oligometastatic breast cancer.

25 min

New imaging technologies for advanced breast cancer

Frédéric Lecouvet, Brussels / Belgium

To highlight the value of whole-body MRI as a highly accurate modern imaging tool for metastatic screening in breast cancer.
To illustrate the specific indications of WB-MRI in advanced breast cancer, from diagnosis of metastasis to response assessment.
To understand the respective roles of WB-MRI and PET/CT and how a patient-specific approach to metastatic disease is currently necessary.

25 min

Optimal use of FDG-PET/CT in breast cancer: new EANM/SNMMI guidelines, endorsed by ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA

Lioe-Fee De Geus-Oei, Leiden / Netherlands

To learn about the evidence-based recommendations to perform 2-[18F]FDG PET/CT in the initial staging, in assessing response to therapy and in assessing recurrence.
To become familiar with the new guidelines.
To understand the role of 2-[18F]FDG-PET/CT in NST breast cancer.

10 min

Panel discussion